COMPANY:

Cleveland Diagnostics

"Cleveland Diagnostics...signed a distribution agreement with Dow BioMedica, a trusted distributor of life science solutions for biotechnology, clinical research organizations, and universities. Under this agreement, Dow BioMedica will exclusively distribute Cleveland Diagnostics’ IsoPSA prostate cancer test in Korea."

"Cleveland Diagnostics, Inc...announced the closing of over $75M in growth capital financing. The financing was led by Novo Holdings, a leading global life sciences investor, responsible for managing the assets of the Novo Nordisk Foundation, along with participation from existing investors as well as a credit facility from Symbiotic Capital. The financing will accelerate Cleveland Diagnostics’ commercial and corporate development goals....Cleveland Diagnostics’ portfolio of oncology related tests will be expanding beyond prostate cancer into additional indications in 2024."

"Cleveland Diagnostics, Inc...announced an agreement designed to expand patient access to Cleveland Diagnostics’ novel prostate cancer test, IsoPSA. Through an agreement with Quest Diagnostics...the nation’s leading provider of diagnostic information services, patients will be able to access IsoPSA and, once ordered by their physician, provide a blood specimen for testing at one of over 2,100 Quest Diagnostics patient service center locations nationwide later this year. With its national logistics network, Quest will transport the specimens to Cleveland Diagnostics’ laboratory for testing. The parties expect physicians will be able to begin offering the test to patients through Quest Diagnostics in the second quarter of 2023."